|Day Low/High||0.76 / 0.79|
|52 Wk Low/High||0.63 / 1.50|
Study showed a markedly reduced rate of Severe OM (WHO Grade = 3): Active Arm (Brilacidin): 2 of 9 patients (22.2 percent); Control Arm (Placebo): 7 of 10 patients (70 percent)
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Study results, through the first two cohorts of patients treated, support Brilacidin as a novel and promising anti-inflammatory drug candidate
Study to help guide Cellceutix in continued development of Brilacidin, including planned foam and oral formulations for hard-to-treat chronic conditions like Ulcerative Colitis and Crohn's Disease
TheStreet's Adam Feuerstein answers readers' questions about biotech stocks.
CEOs of troubled companies tend to launch public tirades against the 'evil' shorts. The rants are often a smokescreen meant to divert investors' attention from problems.
Management to provide Clinical, Regulatory and Financial Updates